Clinical trial
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy…
NCT00455533 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00455533 |
|---|---|
| Title | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer |
| Official title | A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Ixabepilone, Paclitaxel, Cyclophosphamide, Doxorubicin |
| Enrollment | 384 |
| Start date | Oct 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Apr 3, 2007 |
| Last update posted | Feb 24, 2016 |
| Countries | Argentina, Austria, France, Germany, India, Italy, Peru, Philippines, Russia, Singapore, South Korea, Spain and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: